Ads
related to: egfr- Starting LUPKYNIS®
Get info and resources to help
start your patient on LUPKYNIS®.
- Safety & Efficacy Profile
View LUPKYNIS® results in clinical
trials. Adverse reaction info.
- Physician Resources
Tools for you and your practice
to help you prescribe LUPKYNIS®.
- Dosing Information
For HCPs: find LUPKYNIS® dosing
and administration recommendations.
- Connect with a REP
Sign up to receive updates and
HCP materials for LUPKYNIS®.
- Important Safety Info
Visit Official HCP Website
for full product information.
- Starting LUPKYNIS®
Search results
...of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Puma...
Benzinga· 2 hours agoPuma Biotechnology, Inc. PBYI, a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
...Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and...
Morningstar· 2 days agoIn 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 ...
...Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20...
The Woonsocket Call· 1 day agoThe global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins ...
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 11 hours agoThe Phase I/II REZILIENT1 trial (NCT04036682) is an open-label, multi-centre study in NSCLC patients...
Why Is German Biotech Affimed Stock Soaring On Monday?
Benzinga· 45 minutes agoAffimed N.V. AFMD shares are trading higher on Monday. On Saturday, the company announced longer...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 1 day agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Merus reports promising results for lung cancer antibody MCLA-129 By Investing.com
Investing.com· 2 hours agoThe presentation detailed the efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 3 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease ...
Why Affimed Shares Are Soaring - Affimed (NASDAQ:AFMD)
Benzinga· 4 hours agoAffimed N.V. AFMD shares are trading higher Monday after the company announced additional follow-up...
Ads
related to: egfr
